Elodie Burlet

Dr. Elodie Burlet brings over 6 years of experience in the research and development of vaccines to VaxForm. She has worked on the formulation development of a variety of vaccines targeting bacterial and viral pathogens, including Streptococcus pyogenes, Streptococcus Pneumoniae, Staphylococcus Aureus, Rabies, combination vaccine Diphtheria/Tetanus/Pertussis, HIV, Neisseria Meningitis, SARS-CoV-2, as well as immunotherapies targeting non-infectious diseases such as Alzheimer’s and cardiovascular diseases. Dr. Burlet also has extensive experience in aluminum adjuvants production and development, antigen fermentation and purification, assay development, and small-scale final drug product fill finish.

Dr. Burlet was the technical lead on the SBIR Phase 1 NSF-funded project to develop orally administered DTaP vaccine using VaxForm’s patented oral delivery technology and is currently the Principal Investigator on another NSF-funded SBIR Phase 1 project supporting VaxForm’s latest vaccine developmental effort: an oral and thermally stable COVID-19 vaccine.

Dr. Burlet received her Ph.D in Biochemistry and Molecular Biology from Louisiana State University Health Shreveport.